title: A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer.
abstract: Navelbine (vinorelbine, NVB) is the first semisynthetic 5'-nor-vinca-alkaloid selected for clinical trial. NVB has been shown to have a good level of activity against different experimental solid tumors in animals, with low neurotoxicity. In the phase II study, 78 patients with an inoperable non-small-cell lung cancer (NSCLC) were treated with NVB at a weekly dose of 30 mg/m2. No patient had previously received chemotherapy. Twenty-three of the 78 eligible patients showed a partial response (29.4% with a 95% confidence limits: 19.5-39.5). Eight patients were not evaluable and the percentage of partial response were 32.8% in the evaluable patients group. The median response duration was 34 weeks, and the median survival time for the overall population reached 33 weeks. Grade 3-4 leukopenia was seen in 12.5% of cycles. No thrombocytopenia occurred. At the dosage schedule used, NVB seems a very promising agent in the treatment of NSCLC.
authors.affiliation: Service de Pneumologie, CHR de Besançon, France.
authors.forename: A
authors.initials: A
authors.lastname: Depierre
authors.forename: E
authors.initials: E
authors.lastname: Lemarie
authors.forename: G
authors.initials: G
authors.lastname: Dabouis
authors.forename: G
authors.initials: G
authors.lastname: Garnier
authors.forename: P
authors.initials: P
authors.lastname: Jacoulet
authors.forename: J C
authors.initials: JC
authors.lastname: Dalphin
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012026:Reflex, Stretch / Q000187:drug effects; D012074:Remission Induction; D015996:Survival Rate; D013997:Time Factors; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D014747:Vinblastine; D000077235:Vinorelbine